Posts in Uncategorized

ICH M4Q(R2): How the Revised CTD Quality Structure Will Reshape Module 2.3 and Module 3

For more than two decades, the quality part of the Common Technical Document has followed the structure set by ICH M4Q. Its revision, M4Q(R2), changes[…]

Excipient Risk Assessment: Applying the EU Guidelines on Appropriate GMP for Excipients

Excipients make up most of the mass of many medicines, yet they are often the least scrutinised part of the supply chain. Since 2016, EU[…]

Overdose, Abuse, Misuse and Off-Label Use: Handling Special Situations in Pharmacovigilance

Not every pharmacovigilance report describes a medicine used as authorised. Overdose, abuse, misuse, off-label use and occupational exposure are what EU guidance calls “special situations”[…]

eCTD Lifecycle Management: Sequences, Baselines and Submission Gateways

An eCTD dossier is not a single submission but a lifecycle of sequences that builds over the years a product is on the market. Managing[…]

Module 5 Clinical Study Reports: Structuring Clinical Evidence for EU Assessment

Module 5 is usually the largest part of a marketing authorisation dossier, and assessors navigate it under time pressure. A complete tabular listing, study reports[…]

Module 4 Nonclinical Study Reports: Organising the Evidence Behind the Overview

Module 4 holds the nonclinical study reports that support the safety of a medicine before and alongside clinical use. Its structure is fixed by ICH[…]

Module 3 for Biological Medicines: Cell Banks, Viral Safety and Comparability

The CTD quality structure was first written with small molecules in mind, but biological medicines place very different demands on Module 3. Cell substrates, viral[…]

Module 3.2.A and 3.2.R: The Appendices and Regional Information Applicants Overlook

Most attention in Module 3 goes to the drug substance and drug product sections. Yet the appendices in 3.2.A and the regional information in 3.2.R[…]

Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7

Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion,[…]

Manufacturing Process and Process Validation in Module 3.2.P.3: What Assessors Expect

Module 3.2.P.3 describes how the finished product is made and how the applicant knows the process works. EMA’s guideline on process validation for finished products[…]